{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T01:40:19Z","timestamp":1768959619679,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fabry disease (FD) is a multisystemic, progressive, X-linked genetic disorder caused by dysfunction of the enzyme \u03b1-galactosidase A. Symptoms commonly present in childhood in classic patients. Prior studies in classic patients suggest primary presenting features include gastrointestinal (GI) symptoms such as abdominal pain, bloating, and diarrhea. In this longitudinal study, we collected annual questionnaires and medical records from families of 29 children between 3\u2009months and 9.5\u2009years old, including the Rome III questionnaire. We compared symptom detection of abdominal pain, constipation, diarrhea, and bloating via three methods: the Rome III, a simple review of symptoms questionnaire, and pediatrician notes including a review of systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Both questionnaires elicited all GI symptoms more frequently than pediatrician notes (log rank test,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The two questionnaires had weaker agreement for constipation than other symptoms (per kappa statistic) and more similar detection at a younger age. After 24\u2009months, the Rome III outperformed the simple review of symptoms questionnaire (Fisher\u2019s exact test,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Pediatrician notes never recorded bloating or severe episodes of abdominal pain.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Targeted questionnaires elicit early gastrointestinal symptoms in pediatric Fabry disease patients that would otherwise go unnoticed at a standard doctor\u2019s appointment. Based on manual analysis of questionnaire data, a list of questions is suggested to support pediatricians of young patients with FD in recognizing GI symptoms. Use of more targeted and specific questions regarding GI symptoms is warranted in pediatric appointments of patients with FD, with age-appropriate expansion of the questions at 24\u2009months of age. Early detection of symptoms in this population is critical as individual treatment plans are based on symptom onset and as newborn screening is expanding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04168-3","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T12:38:55Z","timestamp":1768912735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted questionnaires improve detection of early gastrointestinal symptoms in young children with Fabry disease"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4236-9223","authenticated-orcid":false,"given":"Anika","family":"Quillin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Waddel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwen","family":"Gunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jared","family":"Druss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Laney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"4168_CR1","unstructured":"Desnick RJ, Ioannou YA, Eng CM \u03b1-Galactosidase A Deficiency: Fabry Disease. in: Valle, DL, Antonarakis, S, Ballabio, A, Beaudet, AL, Mitchell, GA., eds. The online metabolic and molecular bases of inherited disease. McGraw-Hill Education; 2019. Accessed April 16, 2024. https:\/\/ommbid.mhmedical.com\/content.aspx?bookid=2709%26sectionid=225546984."},{"issue":"5","key":"4168_CR2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10545-011-9447-9","volume":"35","author":"MG Bouwman","year":"2012","unstructured":"Bouwman MG, Rombach SM, Schenk E, et al. Prevalence of symptoms in female fabry disease patients: a case-control survey. J Inherit Metab Dis. 2012;35(5):891\u201398.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"4168_CR3","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin RJ, Bissler J, Banikazemi M, et al. Characterization of fabry disease in 352 pediatric patients in the Fabry registry. Pediatr Res. 2008;64(5):550\u201355.","journal-title":"Pediatr Res"},{"issue":"1","key":"4168_CR4","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13023-022-02392-9","volume":"17","author":"M Beck","year":"2022","unstructured":"Beck M, Ramaswami U, Hernberg-St\u00e5hl E, et al. Twenty years of the fabry outcome survey (FOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis. 2022;17(1):238. Published 2022 Jun 20.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"4168_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/gim.2014.120","volume":"17","author":"DA Laney","year":"2015","unstructured":"Laney DA, Peck DS, Atherton AM, et al. Fabry disease in infancy and early childhood: a systematic literature review. Genet Med. 2015;17(5):323\u201330.","journal-title":"Genet Med"},{"key":"4168_CR6","doi-asserted-by":"publisher","first-page":"101891","DOI":"10.1016\/j.gimo.2024.101891","volume":"2","author":"DA Laney","year":"2024","unstructured":"Laney DA, Houde MF, Foley AL, Peck DS, Atherton AM, Manwaring LP, Grange DK, Heese BA, Holida MD, Quillin AL, Vinson R. Prospective characterization of early symptom onset and progression in young pediatric patients with variants in the GLA gene across 5 years: longitudinal data from the fabry MOPPet study. Genet in Med Open. 2024, Jan, 1;2:101891.","journal-title":"Genet in Med Open"},{"issue":"1\u20132","key":"4168_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ymgme.2022.07.010","volume":"137","author":"DP Germain","year":"2022","unstructured":"Germain DP, Altarescu G, Barriales-Villa R, et al. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. Mol Genet Metab. 2022;137(1\u20132):49\u201361.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4168_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","volume":"117","author":"RJ Hopkin","year":"2016","unstructured":"Hopkin RJ, Jefferies JL, Laney DA, et al. The management and treatment of children with fabry disease: a united states-based perspective. Mol Genet Metab. 2016;117(2):104\u201313.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4168_CR9","doi-asserted-by":"publisher","first-page":"106967","DOI":"10.1016\/j.ymgme.2022.106967","volume":"138","author":"RJ Hopkin","year":"2023","unstructured":"Hopkin RJ, Cabrera GH, Jefferies JL, et al. Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: an analysis from the fabry registry. Mol Genet Metab. 2023;138(2):106967.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4168_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00467-023-06050-5","volume":"39","author":"J Avarappattu","year":"2024","unstructured":"Avarappattu J, Gaspert A, Spart\u00e0 G, Rohrbach M. Impact of kidney biopsy on deciding when to initiate enzyme replacement therapy in children with Fabry disease. Pediatr Nephrol. 2024;39(1):131\u201340.","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"4168_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ymgme.2021.12.004","volume":"135","author":"van der Veen Sj","year":"2022","unstructured":"van der Veen Sj, K\u00f6rver, Hirsch A, et al. Early start of enzyme replacement therapy in pediatric male patients with classical fabry disease is associated with attenuated disease progression. Mol Genet Metab. 2022;135(2):163\u201369.","journal-title":"Mol Genet Metab"},{"key":"4168_CR12","unstructured":"Association of Public Health Laboratories. Screened conditions report. NewSTEPs. https:\/\/www.newsteps.org\/data-center\/reports\/screened-conditions-report. Accessed April 21 2024."},{"issue":"6","key":"4168_CR13","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.3390\/ijerph18063320","volume":"18","author":"F Caputo","year":"2021","unstructured":"Caputo F, Lungaro L, Galdi A, Zoli E, Giancola F, Caio G, De Giorgio R, Zoli G. Gastrointestinal involvement in Anderson-Fabry disease: a narrative review. Int J Environ Res Public Health. 2021, Mar, 23;18(6):3320.","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"4168_CR14","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3390\/nu17071194","volume":"17","author":"VN Dargenio","year":"2025","unstructured":"Dargenio VN, Natale M, Castellaneta SP, Grasta GL, Paulucci L, Dargenio C, Francavilla R, Cristofori F. Unraveling the hidden burden of gastrointestinal and nutritional challenges in children with Fabry disease: a systematic review with meta-analysis. Nutrients. 2025;17(7):1194.","journal-title":"Nutrients"},{"issue":"6","key":"4168_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3390\/metabo15060361","volume":"15","author":"V Gragnaniello","year":"2025","unstructured":"Gragnaniello V, Cazzorla C, Gueraldi D, Puma A, Loro C, Burlina AB. The hidden burden: gastrointestinal involvement in lysosomal storage disorders. Metabolites. 2025, May, 29;15(6):361.","journal-title":"Metabolites"},{"issue":"1","key":"4168_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1477-7525-10-116","volume":"10","author":"U Ramaswami","year":"2012","unstructured":"Ramaswami U, Stull DE, Parini R, Pintos-Morell G, Whybra C, Kalkum G, Rohrbach M, Raluy-Callado M, Beck M, Chen WH, Wiklund I. Measuring patient experiences in fabry disease: validation of the Fabry-specific pediatric health and pain questionnaire (FPHPQ). Health And Qual Of Life Outcomes. 2012;10(1):116.","journal-title":"Health And Qual Of Life Outcomes"},{"issue":"3","key":"4168_CR17","doi-asserted-by":"publisher","first-page":"298","DOI":"10.5056\/jnm.2012.18.3.298","volume":"18","author":"S Rajindrajith","year":"2012","unstructured":"Rajindrajith S, Devanarayana NM. Subtypes and symptomatology of irritable bowel syndrome in children and adolescents: a school-based survey using rome iii criteria. J Neurogastroenterol Motil. 2012;18(3):298\u2013304.","journal-title":"J Neurogastroenterol Motil"},{"key":"4168_CR18","doi-asserted-by":"crossref","unstructured":"Pensabene L, Sestito S, Nicoletti A, Graziano F, Strisciuglio P, Concolino D. Gastrointestinal symptoms of patients with Fabry disease. Gastroenterol Res Pract. 2016, 2016;9712831.","DOI":"10.1155\/2016\/9712831"},{"issue":"4","key":"4168_CR19","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/cge.14102","volume":"101","author":"DP Germain","year":"2022","unstructured":"Germain DP, Levade T, Hachulla E, et al. Challenging the traditional approach for interpreting genetic variants: lessons from Fabry disease. Clin Genet. 2022;101(4):390\u2013402.","journal-title":"Clin Genet"},{"issue":"8","key":"4168_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/heartjnl-2019-315933","volume":"106","author":"K Valtola","year":"2020","unstructured":"Valtola K, Nino-Quintero J, Hedman M, et al. Cardiomyopathy associated with the Ala143Thr variant of the \u03b1-galactosidase a gene. Heart. 2020;106(8):609\u201315.","journal-title":"Heart"},{"issue":"6","key":"4168_CR21","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1053\/j.gastro.2013.08.048","volume":"145","author":"AC Ford","year":"2013","unstructured":"Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P. Validation of the Rome iii criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology. 2013;145(6):1262\u201370.e1.","journal-title":"Gastroenterology"},{"issue":"1","key":"4168_CR22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.15403\/jgld-3855","volume":"31","author":"D Radulescu","year":"2022","unstructured":"Radulescu D, Crisan D, Militaru V, et al. Gastrointestinal manifestations and treatment options in Fabry disease patients: a systematic review. J Gastrointestin Liver Dis. 2022;31(1):98\u2013106.","journal-title":"J Gastrointestin Liver Dis"},{"issue":"7","key":"4168_CR23","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1007\/s00431-022-04459-y","volume":"181","author":"R Rexwinkel","year":"2022","unstructured":"Rexwinkel R, Vlieger AM, Saps M, Tabbers MM, Benninga MA. A therapeutic guide on pediatric irritable bowel syndrome and functional abdominal pain-not otherwise specified. Eur J Pediatr. 2022;181(7):2603\u201317.","journal-title":"Eur J Pediatr"},{"issue":"7","key":"4168_CR24","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1007\/s00431-021-04013-2","volume":"180","author":"DF Baaleman","year":"2021","unstructured":"Baaleman DF, Velasco-Ben\u00edtez CA, M\u00e9ndez-Guzm\u00e1n LM, Benninga MA, Saps M. Functional gastrointestinal disorders in children: agreement between Rome III and Rome IV diagnoses. Eur J Pediatr. 2021;180(7):2297\u2013303.","journal-title":"Eur J Pediatr"},{"issue":"5","key":"4168_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11894-020-00760-8","volume":"22","author":"DF Baaleman","year":"2020","unstructured":"Baaleman DF, Di Lorenzo C, Benninga MA, Saps M. The effects of the Rome IV criteria on pediatric gastrointestinal practice. Curr Gastroenterol Rep. 2020;22(5):21.","journal-title":"Curr Gastroenterol Rep"},{"issue":"6","key":"4168_CR26","doi-asserted-by":"publisher","first-page":"e004252","DOI":"10.1161\/CIRCGEN.123.004252","volume":"16","author":"E Monda","year":"2023","unstructured":"Monda E, Diana G, Graziani F, et al. Impact of GLA variant classification on the estimated prevalence of Fabry disease: a systematic review and meta-analysis of screening studies. Circ Genom Precis Med. 2023;16(6):e004252.","journal-title":"Circ Genom Precis Med"},{"key":"4168_CR27","first-page":"101","volume":"8","author":"W Terryn","year":"2013","unstructured":"Terryn W, Vanholder R, Hemelsoet D, et al. Questioning the pathogenic role of the GLA p.Ala143Thr \u201cmutation\u201d in fabry disease: implications for screening studies and ERT. JIMD Rep. 2013;8:101\u201308.","journal-title":"JIMD Rep"},{"issue":"28","key":"4168_CR28","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.3748\/wjg.v22.i28.6547","volume":"22","author":"AP Ferreira-Maia","year":"2016","unstructured":"Ferreira-Maia AP, Matijasevich A, Wang YP. Epidemiology of functional gastrointestinal disorders in infants and toddlers: a systematic review. World J Gastroenterol. 2016;22(28):6547\u201358.","journal-title":"World J Gastroenterol"},{"key":"4168_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jpeds.2016.04.008","volume":"177","author":"ML Lewis","year":"2016","unstructured":"Lewis ML, Palsson OS, Whitehead WE, van Tilburg MAL. Prevalence of functional gastrointestinal disorders in children and adolescents. J Pediatr. 2016;177:39\u201343.e3.","journal-title":"J Pediatr"},{"issue":"20","key":"4168_CR30","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.3748\/wjg.v20.i20.6013","volume":"20","author":"BK Sandhu","year":"2014","unstructured":"Sandhu BK, Paul SP. Irritable bowel syndrome in children: pathogenesis, diagnosis and evidence-based treatment. World J Gastroenterol. 2014;20(20):6013\u201323.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"4168_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/ijns9020031","volume":"9","author":"V Gragnaniello","year":"2023","unstructured":"Gragnaniello V, Burlina AP, Commone A, et al. Newborn screening for fabry disease: current status of knowledge. Int J Neonatal Screen. 2023;9(2):31.","journal-title":"Int J Neonatal Screen"},{"issue":"2","key":"4168_CR32","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ajmg.c.31998","volume":"190","author":"S Viall","year":"2022","unstructured":"Viall S, Dennis A, Yang A. Newborn screening for Fabry disease in Oregon: approaching the iceberg of A143T and variants of uncertain significance. Am J Med Genet C Semin Med Genet. 2022;190(2):206\u201314.","journal-title":"Am J Med Genet C Semin Med Genet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04168-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04168-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04168-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T12:38:57Z","timestamp":1768912737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04168-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4168"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04168-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was approved by the Emory IRB as IRB00072967. Informed consent to participate in the study was obtained from participants (or their parent or legal guardian in the case of children under 16). See Laney et al., 2024 for detailed methods.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Anika Quillin, Hannah Waddel and Jared Druss do not have any competing interests to declare. Gwendolyn Gunn, PhD, MS, CGC, has disclosed that she has received honoraria and research funding as a speaker and registries\/research coordinator for Sanofi Genzyme. These activities are monitored and in compliance with conflict of interest policies at Emory University. Nadia Ali has disclosed that she has received research support from Sanofi Genzyme, Shire Takeda, BioMarin, Amicus, and Pfizer, as well as lecturers\u2019 honoraria from Sanofi Genzyme, BioMarin, Amicus, and Vitaflo. These activities are monitored and in compliance with conflict of interest policies at Emory University. William Wilcox, MD has disclosed research support from AmicusTherapeutics, clinical study contracts with Amicus, Chiesi, Protalix, Sangamo, Sanofi-Genzyme, and 4D Molecular Therapeutics, advisory meeting honoraria from Chiesi and Sanofi-Genzyme, and consultant involvement with Uniqure and Spark Therapeutics. Dawn Jacob Laney, MS, CGC, CCRC, has disclosed that she has received honoraria and research funding as an investigator, researcher, speaker, and board member registries\/coordinator for Sanofi Genzyme; has received research funding and honoraria as an investigator, speaker, and coordinator for Amicus Therapeutics, Chiesi Therapeutics, and Shire (now part of Takeda); and is a co-founder and has stock options for ThinkGenetic, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}